Informed Prostate Cancer Patient Support

Example of a Hypothetical AI-Generated Clinical Visit Transcript and the Resulting Draft Note. AI Medical Scribes: Should Your Doctor's Notes Keep the Full Conversation? AI Medical Scribes: Should Your Doctor's Notes Keep the Full Conversation? BOTTOM LINE UP FRONT: AI scribes that automatically transcribe doctor visits are being widely adopted across healthcare, but most U.S. hospitals are deleting these valuable transcripts immediately after finalizing patient notes—primarily due to malpractice liability fears. This practice prevents researchers from evaluating AI accuracy, studying diagnostic errors, and advancing medical knowledge, while AI companies retain the data to train future products. Experts argue that with proper safeguards, these transcripts represent "digital gold" for improving healthcare quality and safety. The Rise of AI Medical Scribes Artificial intelligence has entered the exam room. AI scribes—software tools powered by large language models—n...

FDA OKs Blood-Based Test to Help Detect High-Grade Prostate Tumors | MedPage Today FDA Approves New Blood Test to Better Detect Aggressive Prostate Cancer BLUF (Bottom Line Up Front): The FDA has approved IsoPSA, a novel blood test that analyzes PSA at the molecular level to more accurately identify men with aggressive prostate cancer. In clinical studies, the test demonstrated 90% sensitivity for detecting high-grade tumors while potentially reducing unnecessary biopsies by 55%, offering men with elevated PSA a more precise tool for deciding whether to proceed with biopsy. Understanding the New Test Men facing elevated PSA levels now have access to a more sophisticated diagnostic tool following the FDA's December 2025 approval of Cleveland Diagnostics' IsoPSA test. Unlike standard PSA testing, which measures only the total amount of prostate-specific antigen in blood, IsoPSA examines the structural variations (isoforms) of the PSA molecule itself to determine whether eleva...